Sign In
Buy IOVA
$4.38
+0.590 (+15.57%)
At Close: Jun 04, 2026
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) investors conce
SAN FRANCISCO--(BUSINESS WIRE)--In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) on behalf of investors co
Iovance Stock Sinks 46%. Here's Why the Biotech Is Tumbling.
11:33am, Friday, 09'th May 2025
The oncology drug maker posts a wider-than-expected loss in the first quarter.
Why Iovance Biotherapeutics Stock Is Crashing Today
11:03am, Friday, 09'th May 2025
Shares of Iovance Biotherapeutics (IOVA -46.06%) were crashing 46.6% lower as of 10:40 a.m. ET on Friday.
No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed
09:38am, Friday, 09'th May 2025
IOVA's Q1'25 product revenue was $49.3M, impacted by production facility maintenance; however, Q2'25 estimates for infusions imply weak growth, despite not being impacted by production. Replimune's RP
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
09:10am, Friday, 09'th May 2025
IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call Transcript
10:01pm, Thursday, 08'th May 2025
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates
06:31pm, Thursday, 08'th May 2025
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.42 per share a year ago.
My 3 Favorite Stocks to Buy Right Now
03:15am, Tuesday, 06'th May 2025
Veteran investors know that the market's recent weakness is more of an opportunity than an omen. Sure, stocks may not have hit their ultimate bottom just yet.
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025
04:01pm, Friday, 02'nd May 2025
SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infi
2 Beaten-Down Stocks With Incredible Upside Potential
05:14am, Wednesday, 30'th Apr 2025
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have signi
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
04:15pm, Wednesday, 23'rd Apr 2025
SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
06:10am, Wednesday, 23'rd Apr 2025
Iovance Biotherapeutics (IOVA 4.38%) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable) or meta
This Biotech Stock Could Be the Best Investment of the Decade
10:00am, Saturday, 19'th Apr 2025
Picking stocks with a relatively narrow timeframe in mind -- and with a particular performance expectation -- can be tricky. Most investors can distinguish between bad, good, and even-better investmen
